Outlook Therapeutics (OTLK) Misses Q3 EPS by 44c
Tweet
Share
E-mailGet Alerts OTLK Hot Sheet
Join SI Premium – FREE
Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.44). Revenue for the quarter came in at $1.51 million.
For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
- BetterLife Pharma files final prospectus for $100M public offering
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
